Mass Spectrometry-based Proteomics in Pre-clinical Drug Discovery
Tools
Tools
Schirle, Markus, Bantscheff, Marcus and Kuster, Bernhard (2012) Mass Spectrometry-based Proteomics in Pre-clinical Drug Discovery. Chemistry & Biology, 19 (1). pp. 72-84. ISSN 1074-5521
Abstract
Pre-clinical stages in the drug discovery process require a multitude of biochemical and genetic assays in order to characterize the effects of drug candidates on cellular systems and model organisms. Early attempts to apply unbiased proteomics techniques for the identification of protein target and off-targets as well as to elucidate the mode-of-action of candidate drug molecules suffered from a striking discrepancy between scientific expectations and what the technology was able to deliver at the time. Dramatic technological improvements in mass spectrometry-based proteomics and novel chemoproteomic strategies have radically changed this situation. This review therefore highlights proteomic approaches suitable for pre-clinical drug discovery illustrated by recent success stories.
| Item Type: | Article |
|---|---|
| Related URLs: | |
| Additional Information: | author can archive post-print (ie final draft post-refereeing); Publisher's version/PDF cannot be used |
| Related URLs: | |
| Date Deposited: | 13 Oct 2015 13:14 |
| Last Modified: | 13 Oct 2015 13:14 |
| URI: | https://oak.novartis.com/id/eprint/6531 |